Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Distinct immune signatures for predicting the immunotherapy efficacy of esophageal squamous cell carcinoma or adenocarcinoma

doi: 10.1007/s00262-024-03904-1

Figure Lengend Snippet: Detecting unique cytokines linked to clinical outcomes in esophageal squamous cell carcinoma and adenocarcinoma separately. a Venn diagram shows genes in the cytokine-cytokine receptor pathway for ESCC and EAC from TCGA, annotated with gene counts in distinct and overlapping categories. b Overall survival of patients with TCGA-ESCC and different expression levels of TNFSF10 and CXCL14. c TNFSF10 and CXCL14 expression comparison between early and advanced ESCC tissues (TCGA). d Survival probabilities of patients with EAC classified by CXCL8 and IL17RB expression levels (TCGA). e CXCL8 and IL17RB expression during EAC progression from early to advanced stages. f TNFSF10 and CXCL14 expression in early and advanced ESCC tissues of Chinese patients. g, h The left panel presents immunohistochemical images illustrating TNFSF10 or CXCL14 staining in tissue microarrays obtained from patients diagnosed with ESCC, arranged sequentially from left to right based on ascending expression levels quantified by the H-score. On the far left, the lowest expression level is shown, followed by a sample in the lowest 33.33 percentile, then a moderate expression sample in the next 33.33 percentile, and finally, the highest expression level on the far right. The right panel displays survival curves stratified by the expression of TNFSF10 and CXCL14, categorized into low and high expression groups based on their H-scores. i, j The left panel displays immunohistochemical staining for CXCL8 or IL17RB in tissue microarrays from patients with EAC, with samples ordered from left to right by increasing H-scores. The sequence starts with the lowest expression level, followed by a sample in the first 33.33 percentile, then a sample with moderate expression in the next percentile, and ends with the highest expression level on the far right. P values were calculated using the Mann–Whitney (log-rank) test. Early stage: Stage 0-II; Advanced stage: Stage III-IV; ns: no significance; * P < 0.05, Mann–Whitney test

Article Snippet: The tissue sections were incubated with primary antibodies against TNFSF10 (Catalog No. ab2056; Abcam), CXCL14 (catalog no. ab137541; Abcam), CXCL8 (catalog no. ab106350; Abcam), IL17RB (Catalog No. AF1207; R&D Systems), CXCL10 (Catalog No. ab306587; Abcam, Cambridge, UK), HIF1α (catalog no. ab51608; Abcam), CSF2 (catalog no. ab316862; Abcam), and NOS2 (catalog no. ab283655; Abcam) (diluted at 1:500 in phosphate-buffered saline) overnight at 4℃.

Techniques: Expressing, Comparison, Immunohistochemical staining, Staining, Sequencing, MANN-WHITNEY

Journal: The Journal of allergy and clinical immunology

Article Title: Blockade of Repulsive guidance molecule b (RGMb) inhibits allergen-induced airways disease

doi: 10.1016/j.jaci.2018.12.1022

Figure Lengend Snippet: IL-25 but not IL-33 signaling is required for development of OVA-induced AHR ST2−/− (A, B), IL-17RB−/− (C,D), or WT mice sensitized and challenged with OVA or saline as in Fig 1A were assessed for AHR on day 10. Mice in (A) were treated with control mAb or RGMb mAb on day -1, 4 and 8 as indicated. B,D. Inflammatory cells in BAL fluid (cells/lung) of the mice in A and C. E. Expression of il-17rb, il-25, and il-13 mRNA in lung of WT mice at 3h and 24h after last allergen challenge, measured by qPCR. GAPDH was used as an internal control. Values are normalized to saline mice at 3h. A, C, n=4. Data shown are means ± SD. * P<0.05; ** P<0.01; *** P<0.005. Two-way ANOVA with the Bonferroni post-hoc test. B, D, E, unpaired t test.

Article Snippet: IL-25 (Mm00499822_m1), IL-17RB (Mm00444709_m1).

Techniques: Expressing